The U.S. Food and Drug Administration recently announced the issuance of 30 warning letters to telehealth companies for making false or misleading claims regarding compounded GLP-1 products offered on their websites. “It’s a new era. We are paying close attention to misleading claims being made by telehealth and pharma companies across all media platforms—and taking...
